Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
Leanne M. Ward(Children's Hospital of Eastern Ontario), Erik A. Imel(Indiana University – Purdue University Indianapolis), Jill H. Simmons(Vanderbilt University), Hae Il Cheong(Seoul National University Children's Hospital), Anthony A. Portale(University of California, San Francisco), Alison Skrinar, Mary Scott Roberts(Bridge Pharma (United States)), Michael P. Whyte(Shriners Hospitals for Children - St. Louis), Craig F. Munns(Children's Medical Research Institute), Ola Nilsson(Karolinska University Hospital), Raja Padidela(University of Groningen), Gary S. Gottesman(Shriners Hospitals for Children - St. Louis), Meng Mao(Guiyang Medical University), Angel Chen(Yale University), Francis H. Glorieux(Shriners Hospitals for Children - Canada), Wolfgang Högler(Johannes Kepler University of Linz), Noriyuki Namba(Osaka Hospital)
Cited by 78
Related Papers
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Global Consensus Recommendations on Prevention and Management of Nutritional Rickets
|The Journal of Clinical Endocrinology & Metabolism|2016|1.1k
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China
|The Lancet|2021|579
Burosumab Therapy in Children with X-Linked Hypophosphatemia
|New England Journal of Medicine|2018|479